Earlier this month, the US President signed a landmark executive order aimed at delivering “most favored nation” (MFN) pricing for prescription drugs in the United States. As outlined in the official White House release and covered by Reuters, the order seeks to tie US drug prices to those paid in other developed nations, potentially slashing prices by up to 59%. While much of the media focus has been on the implications for American patients, this shift also raises important